Literature DB >> 34013604

Engineering the Deformability of Albumin-Stabilized Emulsions for Lymph-Node Vaccine Delivery.

Tiantian Song1,2, Yufei Xia2,3,4, Yiqun Du2,5, Michael W Chen6, Hong Qing1, Guanghui Ma2,3,4.   

Abstract

A major challenge in vaccine delivery is to achieve robust lymph-node (LN) accumulation, which can capitalize on concentrated immunocytes and cytokines in LNs to stimulate the onset and persistence of adaptive immune responses. Previous attempts at developing vaccine delivery systems have focused on the sizes, charges, or surface ligands but not on their deformability. In fact, the LN homing of antigen-presenting cells depends on deformability to pass through the cellular gaps. Herein, the deformability of albumin-stabilized emulsions is engineered. Owing to self-adaptive deformability, the droplets (≈330 nm) can attach to and deform between cells and adjust their sizes to pass through the endothelial gaps (20-100 nm), favoring direct LN transfer (intercellular pathway). Additionally, owing to relatively large sizes, some emulsions can be retained at the administration sites for potent antigen uptake and activation of APCs as well as LN-targeted delivery of vaccines (intracellular pathway). Compared with solid particles, the dual LN transfer strategy evidently enhances antigen accumulation and activation of LN drainage, potently stimulates cellular immune responses, and increases the survival rate of tumor-bearing mice. Thus, the deformability of albumin-stabilized droplets may offer an efficient strategy for potent LN targeting and enhanced vaccinations.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  albumin-stabilized emulsions; deformability; lymph node targeting; vaccine delivery systems; vaccines

Mesh:

Substances:

Year:  2021        PMID: 34013604     DOI: 10.1002/adma.202100106

Source DB:  PubMed          Journal:  Adv Mater        ISSN: 0935-9648            Impact factor:   30.849


  5 in total

1.  Ultrahigh efficient emulsification with drag-reducing liquid gating interfacial behavior.

Authors:  Shijie Yu; Yuan Jing; Yi Fan; Linghu Xiong; Huimeng Wang; Jinmei Lei; Yunmao Zhang; Jing Liu; Shuli Wang; Xinyu Chen; Hao Sun; Xu Hou
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-11       Impact factor: 12.779

2.  Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapy.

Authors:  Yingying Shi; Yu Liu; Jiaxin Huang; Zhenyu Luo; Xuemeng Guo; Mengshi Jiang; Xiang Li; Yichao Lu; Xu Liu; Xinyu Shan; Lihua Luo; Jian You
Journal:  Theranostics       Date:  2022-04-24       Impact factor: 11.600

Review 3.  Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.

Authors:  Ting Cai; Huina Liu; Shun Zhang; Jing Hu; Lingxiao Zhang
Journal:  J Nanobiotechnology       Date:  2021-11-25       Impact factor: 10.435

Review 4.  In vivo fate and intracellular trafficking of vaccine delivery systems.

Authors:  Jaiwoo Lee; Dongyoon Kim; Junho Byun; Yina Wu; Jinwon Park; Yu-Kyoung Oh
Journal:  Adv Drug Deliv Rev       Date:  2022-05-10       Impact factor: 17.873

5.  Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy.

Authors:  Hu Chen; Pengfei Zhang; Yesi Shi; Chao Liu; Qianqian Zhou; Yun Zeng; Hongwei Cheng; Qixuan Dai; Xing Gao; Xiaoyong Wang; Gang Liu
Journal:  J Nanobiotechnology       Date:  2022-02-02       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.